Europe
Pherecydes Pharma and BIOASTER, the French Technology Research Institute for Microbiology and Infectious Diseases, announce the signing of a collaboration agreement.
Largest off-the-shelf diploid KO library, over 2,800 cell lines
For quite some time, the focus of the cause of Alzheimer’s disease was on beta-amyloid, a protein that accumulates in the brains of individuals with the disease and which appears to cause at least some of the damage that results in memory and cognition issues. There are other candidates, and research appears to be heating up on the role of inflammation.
Acquired assets from NCARDIA AG include IP portfolio, IPSC-based cellular products and an experienced stem cell biology team
Board appointment will help guide target identification and drug discovery
Phase 1/2 trial to be HOOKIPA’s first clinical trial in immuno-oncology
Acacia Pharma Group plc welcomes an editorial published in the leading peer-reviewed journal Anesthesia & Analgesia, accompanying the print publication of results from its positive Phase 3 clinical trial of BARHEMSYS® as treatment of post-operative nausea & vomiting in patients who had not received prior prophylaxis*.
Targeted drugs for breast and lung cancer could be used together to overcome resistance to treatment in several different tumour types, a new study shows.
In late June, Minovia Therapeutics dosed the first patient in a Phase I/II clinical trial with Pearson syndrome. The company is one of the first to make headway in treating rare mitochondrial diseases.
How can you selectively target and destroy cancerous T-cells using other T-cells? This question has plagued researches hoping to apply chimeric antigen receptor (CAR) T-cell therapies to T-cell cancers.
PRESS RELEASES